Merck: presents results of HIV study

(CercleFinance.com) - Gilead Sciences and Merck have announced new results from a Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor.


These late-breaking data were presented at an oral session at IDSemaine 2024, in Los Angeles from 16-19 October.

The new investigational combination regimen moves into phase 3 and has the potential to become the first weekly oral HIV treatment.

Single-pill daily regimens have helped transform HIV care, but can be difficult to maintain for some people. New HIV treatment options that allow less frequent oral dosing have the potential to help support adherence and combat the stigma faced by some people on daily oral therapy, Merck said.

We are pleased to see these encouraging 48-week data for this once-a-week oral combination regimen and to move into Phase 3 clinical trials in collaboration with Gilead.


Copyright (c) 2024 CercleFinance.com. All rights reserved.